Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
Context Therapeutics (Nasdaq: CNTX) has announced key appointments to support the development of its clinical-stage T cell engaging assets for solid tumors. Dr. Claudio Dansky Ullmann joins as Chief Medical Officer, bringing over 30 years of experience in oncology therapeutics development. Karen Andreas, M.S. is appointed as Vice President of Clinical Operations, with almost 20 years of biopharma experience.
These appointments come as Context advances its product candidates, CTIM-76 and CT-95, into Phase 1 clinical trials. The company is granting stock options to Dr. Dansky Ullmann and other new employees as inducement awards, subject to vesting conditions and Nasdaq listing rules.
Context Therapeutics (Nasdaq: CNTX) ha annunciato importanti nomine per supportare lo sviluppo dei suoi asset in fase clinica di engagment delle cellule T per i tumori solidi. Il Dott. Claudio Dansky Ullmann entra come Direttore Medico, portando con sé oltre 30 anni di esperienza nello sviluppo di terapie oncologiche. Karen Andreas, M.S. è stata nominata Vicepresidente delle Operazioni Cliniche, con quasi 20 anni di esperienza nel settore biofarmaceutico.
Queste nomine avvengono mentre Context porta avanti i suoi candidati di prodotto, CTIM-76 e CT-95, nelle fasi di sperimentazione clinica di Fase 1. L'azienda sta concedendo opzioni su azioni al Dott. Dansky Ullmann e agli altri nuovi dipendenti come premi di induzione, soggetti a condizioni di maturazione e alle regole di quotazione del Nasdaq.
Context Therapeutics (Nasdaq: CNTX) ha anunciado nombramientos clave para apoyar el desarrollo de sus activos en etapa clínica que involucran células T para tumores sólidos. El Dr. Claudio Dansky Ullmann se une como Director Médico, aportando más de 30 años de experiencia en el desarrollo de terapias oncológicas. Karen Andreas, M.S. es nombrada Vicepresidenta de Operaciones Clínicas, con casi 20 años de experiencia en biopharma.
Estos nombramientos se dan a medida que Context avanza con sus candidatos a producto, CTIM-76 y CT-95, en ensayos clínicos de Fase 1. La empresa otorgará opciones sobre acciones al Dr. Dansky Ullmann y a otros nuevos empleados como premios de inducción, sujetos a condiciones de consolidación y a las normas de cotización de Nasdaq.
Context Therapeutics (Nasdaq: CNTX)는 고형 종양을 위한 T 세포 참여 자산의 임상 단계 개발을 지원하기 위해 주요 인사를 발표했습니다. 클라우디오 단스키 울만 박사가 최고 의학 책임자로 합류하며, 종양학 치료제 개발 분야에서 30년 이상의 경험을 쌓고 있습니다. 카렌 안드레아스, M.S.는 거의 20년의 생명공학 경험을 바탕으로 임상 운영 부사장으로 임명되었습니다.
이번 인사는 Context가 CTIM-76 및 CT-95을 제1상 임상 시험으로 진행하고 있는 가운데 이루어졌습니다. 회사는 단스키 울만 박사와 기타 신규 직원들에게 수여 조건 및 나스닥 상장 규칙에 따라 스톡 옵션을 제공하고 있습니다.
Context Therapeutics (Nasdaq: CNTX) a annoncé des nominations clés pour soutenir le développement de ses actifs d'engagement des cellules T en phase clinique pour les tumeurs solides. Le Dr Claudio Dansky Ullmann rejoint en tant que directeur médical, apportant plus de 30 ans d'expérience dans le développement de thérapies oncologiques. Karen Andreas, M.S. est nommée vice-présidente des opérations cliniques, avec près de 20 ans d'expérience dans le secteur biopharmaceutique.
Ces nominations interviennent alors que Context fait progresser ses candidats produits, CTIM-76 et CT-95, vers des essais cliniques de Phase 1. L'entreprise accordera des options d'achat d'actions au Dr Dansky Ullmann et à d'autres nouveaux employés en tant que récompenses d'incitation, sous réserve de conditions de consolidation et des règles d'inscription au Nasdaq.
Context Therapeutics (Nasdaq: CNTX) hat wichtige Ernennungen bekannt gegeben, um die Entwicklung seiner klinischen T-Zellen-Engagementressourcen für solide Tumoren zu unterstützen. Dr. Claudio Dansky Ullmann tritt als Chief Medical Officer bei, mit über 30 Jahren Erfahrung in der Entwicklung von Onkologie-Therapeutika. Karen Andreas, M.S. wird zur Vizepräsidentin für klinische Operationen ernannt und bringt nahezu 20 Jahre Erfahrung in der Biopharma-Branche mit.
Diese Ernennungen erfolgen, während Context seine Produktkandidaten, CTIM-76 und CT-95, in die klinischen Phase-I-Studien vorantreibt. Das Unternehmen gewährt Dr. Dansky Ullmann und anderen neuen Mitarbeitern Aktienoptionen als Anreizprämien, die an Vesting-Bedingungen und die Vorschriften zur Nasdaq-Notierung gebunden sind.
- Appointment of experienced CMO with 30+ years in oncology therapeutics development
- Addition of VP of Clinical Operations with 20 years of biopharma experience
- Advancement of two product candidates (CTIM-76 and CT-95) into Phase 1 clinical trials
- Granting of stock options to new employees as retention incentives
- None.
Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations
Appointments support the development of the Company’s two clinical-stage T cell engaging assets to treat solid tumors
PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer (“CMO”) and Karen Andreas, M.S. as Vice President, Clinical Operations.
“We are thrilled to welcome Dr. Dansky Ullmann and Ms. Andreas to our team at this exciting time as the Company advances its product candidates, CTIM-76 and CT-95, into Phase 1 clinical trials,” said Martin Lehr, CEO of Context. “Dr. Dansky Ullmann and Ms. Andreas are industry veterans with deep expertise in oncology and T cell therapies, and a proven track record of advancing programs through clinical development.”
Dr. Dansky Ullmann brings over 30 years of experience in early and late-stage oncology therapeutics development. Most recently, he was the CMO at Avenge Bio, where Dr. Dansky Ullmann guided the clinical advancement of AVB-001 allogeneic cell therapy for ovarian cancer. Prior to Avenge, Dr. Dansky Ullmann was CMO at MaxCyte where he was responsible for the development of the CARMA™ chimeric antigen receptor (CAR) therapy program, including MCY-M11, a mesothelin-targeting CAR therapy. Previously, he was the Senior Vice President, Head of Clinical Development at Infinity Pharmaceuticals, where he led the development of Copiktra® through FDA approval and eganelisib through first in human studies. Earlier, he was Global Clinical Lead in the Oncology Therapy Area Unit at Takeda Pharmaceuticals. Before, Dr. Dansky Ullmann was a Senior Investigator in the Cancer Therapy Evaluation Program at the National Cancer Institute, where he was involved in the strategic development of novel agents through Phase 1-3 clinical trials. Dr. Dansky Ullmann earned his M.D. at the School of Medicine, Universidad de Buenos Aires and completed his medical oncology training at Guemes Private Hospital, Buenos Aires.
“I am excited to join the leadership team at Context, which is focused on building an innovative portfolio of clinical stage T cell engaging bispecific therapeutics,” said Dr. Dansky Ullmann. “I look forward to contributing to the team to help bring potential best-in-class and first-in-class treatments to patients in need.”
Ms. Andreas’ biopharma career spans almost 20 years in multiple cross-functional roles across the drug development process, maintaining a primary focus in oncology at small to midsize companies. Prior to joining Context, Ms. Andreas was Vice President, Clinical Operations at Avenge Bio where she was responsible for oversight of all clinical trial activities, clinical operations strategy, planning, and execution for a first in human allogeneic cell therapy for ovarian cancer. Previously, at Boston Pharmaceuticals, Ms. Andreas led clinical operations and program management for zeteletinib through proof of concept and other oncology assets through early development. Ms. Andreas also spent 10 years with Merrimack Pharmaceuticals in various roles advancing multiple oncology and immunology-focused assets and three years at ArQule advancing the company's first early-stage studies. Ms. Andreas holds a bachelor’s degree in biology from Colby College and a Master of Science from Tufts University School of Medicine.
Ms. Andreas stated, “I look forward to working with the entire Context team and utilizing my clinical operations background to support the advancement of the Company’s two clinical stage assets, CTIM-76 and CT-95.”
Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
In connection with the employment of Dr. Dansky Ullmann, the Company will grant a non-qualified stock option award in an amount of 202,170 shares of the Company's common stock as an inducement material to him accepting employment with the Company. Such stock option will have an exercise price equal to the closing price of the Company’s common stock as reported by Nasdaq as of the close of market on August 1, 2024, which will be the date of grant.
The Company also hired an additional employee on August 1, 2024 and anticipates two additional hires starting on August 12, 2024. These employees will be granted non-qualified stock option awards in an aggregate amount of 115,237 shares of the Company's common stock as an inducement material to each of them accepting employment with the Company, with an exercise price equal to the closing price of the Company’s common stock as reported on Nasdaq as of the close of market on the date of commencement of such employee’s employment.
All such stock options will vest as to
About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing medicines for solid tumors that is building an innovative portfolio of clinical-stage T cell engaging bispecific therapeutics. Product candidates include CTIM-76, a Claudin 6 x CD3 bispecific antibody, and CT-95, a mesothelin x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the new appointments to support the Company and the advancement of its product candidates; (ii) the potential benefits, characteristics, safety and side effect profile of our product candidates, (iii) the ability of our product candidates to have benefits, characteristics, manufacturability, and a side effect profile that is differentiated and/or better than third party product candidates, (iv) the likelihood data will support future development of our product candidates, and (v) the likelihood of obtaining regulatory approval for our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
Investor Relations Contact:
Jennifer Minai-Azary
Context Therapeutics
IR@contexttherapeutics.com
FAQ
Who are the new key appointments at Context Therapeutics (CNTX)?
What are the main product candidates Context Therapeutics (CNTX) is advancing?
What is the focus of Context Therapeutics' (CNTX) clinical development?
What type of stock options is Context Therapeutics (CNTX) granting to new employees?
